Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma

Abstract Background The SWI/SNF complex is an important chromatin remodeler, commonly dysregulated in cancer, with an estimated mutation frequency of 20%. ARID1A is the most frequently mutated subunit gene. Almost nothing is known about the other familiar members of the SWI/SNF complexes, SMARCA2 (B...

Full description

Bibliographic Details
Main Authors: Simon Schallenberg, Julian Bork, Ahlem Essakly, Hakan Alakus, Reinhard Buettner, Axel M. Hillmer, Christiane Bruns, Wolfgang Schroeder, Thomas Zander, Heike Loeser, Florian Gebauer, Alexander Quaas
Format: Article
Language:English
Published: BMC 2020-01-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-019-6425-3
_version_ 1818866119270727680
author Simon Schallenberg
Julian Bork
Ahlem Essakly
Hakan Alakus
Reinhard Buettner
Axel M. Hillmer
Christiane Bruns
Wolfgang Schroeder
Thomas Zander
Heike Loeser
Florian Gebauer
Alexander Quaas
author_facet Simon Schallenberg
Julian Bork
Ahlem Essakly
Hakan Alakus
Reinhard Buettner
Axel M. Hillmer
Christiane Bruns
Wolfgang Schroeder
Thomas Zander
Heike Loeser
Florian Gebauer
Alexander Quaas
author_sort Simon Schallenberg
collection DOAJ
description Abstract Background The SWI/SNF complex is an important chromatin remodeler, commonly dysregulated in cancer, with an estimated mutation frequency of 20%. ARID1A is the most frequently mutated subunit gene. Almost nothing is known about the other familiar members of the SWI/SNF complexes, SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1), in oesophageal adenocarcinoma (EAC). Methods We analysed a large cohort of 685 patients with EAC. We used four different antibodies to detect a loss-of-protein of ARID1A BRM, BRG1 and INI1 by immunohistochemistry and correlated these findings with molecular and clinical data. Results Loss of ARID1A, BRG1, BRM and INI1 was observed in 10.4, 3.4, 9.9 and 2% of EAC. We found a co-existing protein loss of ARID1A and BRM in 9.9% and of ARID1A and BRG1 in 2.2%. Patients with loss of ARID1A and TP53 wildtype EACs showed a shortened overall survival compared with AIRDA1A-positive tumours [median overall survival was 60.1 months (95%CI 1.2–139.9 months)] in patients with ARIDA-1A expression and 26.2 months (95%CI 3.7–19.1 months) in cases of ARIDA-1A loss (p = 0.044). Tumours with loss or expression of ARID1A and TP53 loss were not associated with a difference in survival. Only one tumour revealed high microsatellite instability (MSI-H) with concomitant ARID1A loss. All other ARID1A loss-EACs were microsatellite-stable (MSS). No predictive relevance was seen for SWI/SNF-complex alterations and simultaneous amplification of different genes (PIK3CA, KRAS, c-MYC, MET, GATA6, ERBB2). Conclusion Our work describes, for the first time, loss of one of the SWI/SNF ATPase subunit proteins in a large number of adenocarcinomas of the oesophagus. Several papers discuss possible therapeutic interventions for tumours showing a loss of function of the SWI/SNF complex, such as PARP inhibitors or PI3K and AKT inhibitors. Future studies will be needed to show whether SWI/SNF complex-deficient EACs may benefit from personalized therapy.
first_indexed 2024-12-19T10:58:22Z
format Article
id doaj.art-e10e4a042e8d4a9caa143e89f259d80d
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-12-19T10:58:22Z
publishDate 2020-01-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-e10e4a042e8d4a9caa143e89f259d80d2022-12-21T20:24:44ZengBMCBMC Cancer1471-24072020-01-0120111210.1186/s12885-019-6425-3Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinomaSimon Schallenberg0Julian Bork1Ahlem Essakly2Hakan Alakus3Reinhard Buettner4Axel M. Hillmer5Christiane Bruns6Wolfgang Schroeder7Thomas Zander8Heike Loeser9Florian Gebauer10Alexander Quaas11Institute of Pathology, University of CologneInstitute of Pathology, University of CologneInstitute of Pathology, University of CologneDepartment of General, Visceral and Cancer Surgery, University of CologneInstitute of Pathology, University of CologneInstitute of Pathology, University of CologneDepartment of General, Visceral and Cancer Surgery, University of CologneDepartment of General, Visceral and Cancer Surgery, University of CologneDepartment I of Internal Medicine, Center for Integrated Oncology (CIO)University of CologneInstitute of Pathology, University of CologneDepartment of General, Visceral and Cancer Surgery, University of CologneInstitute of Pathology, University of CologneAbstract Background The SWI/SNF complex is an important chromatin remodeler, commonly dysregulated in cancer, with an estimated mutation frequency of 20%. ARID1A is the most frequently mutated subunit gene. Almost nothing is known about the other familiar members of the SWI/SNF complexes, SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1), in oesophageal adenocarcinoma (EAC). Methods We analysed a large cohort of 685 patients with EAC. We used four different antibodies to detect a loss-of-protein of ARID1A BRM, BRG1 and INI1 by immunohistochemistry and correlated these findings with molecular and clinical data. Results Loss of ARID1A, BRG1, BRM and INI1 was observed in 10.4, 3.4, 9.9 and 2% of EAC. We found a co-existing protein loss of ARID1A and BRM in 9.9% and of ARID1A and BRG1 in 2.2%. Patients with loss of ARID1A and TP53 wildtype EACs showed a shortened overall survival compared with AIRDA1A-positive tumours [median overall survival was 60.1 months (95%CI 1.2–139.9 months)] in patients with ARIDA-1A expression and 26.2 months (95%CI 3.7–19.1 months) in cases of ARIDA-1A loss (p = 0.044). Tumours with loss or expression of ARID1A and TP53 loss were not associated with a difference in survival. Only one tumour revealed high microsatellite instability (MSI-H) with concomitant ARID1A loss. All other ARID1A loss-EACs were microsatellite-stable (MSS). No predictive relevance was seen for SWI/SNF-complex alterations and simultaneous amplification of different genes (PIK3CA, KRAS, c-MYC, MET, GATA6, ERBB2). Conclusion Our work describes, for the first time, loss of one of the SWI/SNF ATPase subunit proteins in a large number of adenocarcinomas of the oesophagus. Several papers discuss possible therapeutic interventions for tumours showing a loss of function of the SWI/SNF complex, such as PARP inhibitors or PI3K and AKT inhibitors. Future studies will be needed to show whether SWI/SNF complex-deficient EACs may benefit from personalized therapy.https://doi.org/10.1186/s12885-019-6425-3SWI/SNF-complexLoss-of-functionOesophageal adenocarcinomaTP53 lossHeterogeneity
spellingShingle Simon Schallenberg
Julian Bork
Ahlem Essakly
Hakan Alakus
Reinhard Buettner
Axel M. Hillmer
Christiane Bruns
Wolfgang Schroeder
Thomas Zander
Heike Loeser
Florian Gebauer
Alexander Quaas
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
BMC Cancer
SWI/SNF-complex
Loss-of-function
Oesophageal adenocarcinoma
TP53 loss
Heterogeneity
title Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
title_full Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
title_fullStr Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
title_full_unstemmed Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
title_short Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
title_sort loss of the swi snf atpase subunit members smarcf1 arid1a smarca2 brm smarca4 brg1 and smarcb1 ini1 in oesophageal adenocarcinoma
topic SWI/SNF-complex
Loss-of-function
Oesophageal adenocarcinoma
TP53 loss
Heterogeneity
url https://doi.org/10.1186/s12885-019-6425-3
work_keys_str_mv AT simonschallenberg lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT julianbork lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT ahlemessakly lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT hakanalakus lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT reinhardbuettner lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT axelmhillmer lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT christianebruns lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT wolfgangschroeder lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT thomaszander lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT heikeloeser lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT floriangebauer lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma
AT alexanderquaas lossoftheswisnfatpasesubunitmemberssmarcf1arid1asmarca2brmsmarca4brg1andsmarcb1ini1inoesophagealadenocarcinoma